# J.P. MORGAN — INDIA EQUITY RESEARCH (FORMAT REPLICATION) > **Note:** This is an AI-generated research report prepared in the *style/format* of J.P. Morgan > sell-side research. It is **not** actual J.P. Morgan research and is not affiliated with, endorsed > by, or produced by JPMorgan Chase & Co. For information and illustration only — not investment advice. --- ## BSE Limited (BSE.NS — Financial Exchanges) | | | |---|---| | **Rating** | **UNDERWEIGHT** | | **Price Target** | **₹2,400** (12-month) | | **Current Price** | ₹3,328 (close, 27-Aug-2026) | | **Implied Downside** | **-28%** | | **52-Week Range** | ₹2,022 — ₹4,447 (price ~25% below the high) | | **Market Cap** | ₹1,35,549 Cr (~US$15.4bn) | | **Shares Outstanding** | 411.9 mn (FV ₹2) | | **Net Cash / Share** | ₹134 (₹5,503 Cr net cash — debt free) | | **Dividend (FY26)** | ₹10/share; yield 0.30% | | **Analyst** | Cline Research (AI-generated, JPM format) | --- ## Price Target Basis: 30x our FY28E EPS of ₹80, discounted for regulatory and competitive risk We value BSE on ~30x our FY28E EPS of ₹80 — a sharp de-rating from the current 48x trailing / ~41x forward multiple — reflecting (1) the cyclical, regulatory-exposed nature of the ~74% of revenue that comes from derivatives transaction charges, (2) the structural primacy of NSE in Indian derivatives, and (3) the law of large numbers as 60%+ revenue growth collides with a ₹5,800 Cr TTM revenue base and flattening sequential prints (Q1FY27 revenue was **flat QoQ** at ₹1,566 Cr). Our PT implies ~10.5x our FY28E book value of ~₹230 — still a premium to global exchange peers (CME ~4x, ICE ~6x, Deutsche Börse ~4x book) — and we see asymmetric risk to consensus, which remains anchored to a growth story whose easy decade of share gains is behind it. **Valuation scenarios:** | Scenario | FY28E EPS | Target multiple | Price | Implied return | Key assumption | |---|---|---|---|---|---| | **Bear** | ₹70 | 22x | ₹1,540 | -54% | Further SEBI tightening; expiry-day turf war; volumes mean-revert | | **Base** | ₹80 | 30x | ₹2,400 | -28% | Growth decelerates to low-teens; multiple normalizes | | **Bull** | ₹92 | 45x | ₹4,140 | +24% | Volume momentum persists; NSE response limited | Risk-reward is unattractive: we estimate ~-54% / -28% / +24% across bear/base/bull, skewed to the downside given that the bull case requires the *status quo* of peak regulatory forbearance and peak retail derivatives speculation to persist. --- ## Investment Thesis — Five reasons we are UNDERWEIGHT ### 1. Valuation prices in perfection at the peak of a volume cycle (High conviction) At ₹3,328, BSE trades at **47.9x trailing earnings, ~40.8x forward earnings, ~17x consolidated book, ~23x sales and ~29x EV/EBITDA** — for a business whose dominant revenue line (transaction charges: ₹3,795 Cr in FY26 = 74% of revenue) is a **function of daily options turnover, not a contractual or recurring annuity**. Global exchange peers with equivalent or better moats trade at a fraction of these multiples. BSE's FY22–FY26 earnings CAGR of ~77% is being capitalized as if it were durable; we believe it was a one-time re-rating of (a) share gains in index options post-2021, (b) the retail speculation frenzy, and (c) near-zero incremental cost. The stock is a 2,000%+ 5-year tenbagger — expectations are embedded. ### 2. Regulatory dependency is existential, not peripheral (High conviction) BSE's earnings are a levered call option on SEBI's tolerance of retail index-options speculation. The evidence is already in the numbers: when SEBI tightened F&O rules (larger contract sizes, one weekly expiry per exchange, upfront premium collection) in late 2024, BSE's **Dec-2024 quarter revenue fell QoQ to ₹768 Cr and operating margin collapsed from 56% to 31%**. The recovery since happened *despite* regulation, not because of it. SEBI's own studies show ~9 in 10 retail F&O traders lose money — the political economy points to further tightening (expiry-day rationalization across exchanges, margin enhancements, potential turnover levies), not loosening. Each incremental rule change disproportionately hits the high-velocity options flow that drives BSE's transaction charges. ### 3. The moat is NSE's, not BSE's (Medium-high conviction) BSE's derivatives franchise is effectively a single-product bet on the Sensex/Sensex-50 options complex, competing against NSE's Nifty franchise, which retains the overwhelming majority of notional derivatives market share. BSE's share gains came from aggressive pricing — i.e., **take-rate sacrifice** — and from hosting the second weekly expiry. NSE's superior liquidity pool, index licensing, and institutional mindshare cap BSE's ability to raise pricing; any expiry-day rationalization by SEBI is a direct threat to the primary engine of BSE's growth. Cash equities, currency, and the StAR MF platform are valuable but low-take-rate businesses that cannot carry a 48x multiple. ### 4. Growth is decelerating exactly when the multiple demands acceleration (High conviction) Q1FY27 (Jun-26) revenue of **₹1,566 Cr was flat sequentially** (Mar-26: ₹1,564 Cr) after nine consecutive quarters of QoQ growth. Margins have peaked: OPM of ~67% in H2FY26 leaves little headroom, while costs are normalizing upward (new headquarters, technology/colocation build-out, clearing-corporation ambitions, compliance). We model FY27E revenue growth decelerating to ~+15% from +60% in FY26 and +105% in FY25. On a 41x forward multiple, deceleration of this magnitude is rarely absorbed without multiple compression. ### 5. Ownership structure amplifies downside (Medium conviction) Public shareholding is ~54%, with retail shareholders growing from ~2.0 lakh (Sep-22) to ~10.0 lakh accounts — a classic late-cycle retail-concentration signature. FII ownership has risen to ~21%. Momentum, not fundamentals, dominates the flow; in an Indian market drawdown or a regulatory shock, BSE's high beta to derivatives volumes cuts both ways. The 0.30% dividend yield provides no valuation support, and buybacks are constrained by exchange capital norms. --- ## Where consensus may be wrong The bull narrative ("structural India financialization + BSE share-gain flywheel + 65% margins forever") treats a **volume-cycle business with a price-taker regulatory profile** as a subscription-like growth compounder. We believe consensus (1) underweights the probability of further SEBI tightening, (2) extrapolates peak take-rate/share dynamics against NSE's response, and (3) applies an unwarranted scarcity premium to India's *second* exchange. --- ## Financial Summary (JPM-style table) | ₹ mn unless stated | FY2023A | FY2024A | FY2025A | FY2026A | TTM (Jun-26) | FY2027E | FY2028E | |---|---|---|---|---|---|---|---| | Revenue | 9,257 | 15,682 | 32,120 | 51,243 | 57,884 | ~66,500 | ~75,000 | | Revenue growth | 9.9% | 69.4% | 104.8% | 59.5% | 61.4% | ~15% | ~13% | | Operating income | 2,706 | 8,505 | 21,615 | 39,580 | 45,194 | ~44,000 | ~48,000 | | Operating margin | 29.2% | 54.2% | 67.3% | 77.2% | 78.1% | ~66% | ~64% | | Net income | 2,207 | 7,784 | 13,259 | 24,970 | 28,316 | ~31,000 | ~33,000 | | EPS (₹, post-split) | 5.35 | 18.89 | 32.18 | 60.61 | 68.74 | ~75 | ~80 | | ROE | 6.4% | 18.3% | 28.6% | 37.1% | ~42% | ~40% | ~35% | | P/E (x, at ₹3,328) | 622x | 176x | 103x | 54.9x | 48.4x | 44.4x | 41.6x | | P/B (x) | 39.1x | 31.7x | 24.4x | 17.1x | ~17x | ~15x | ~13x | | Net cash (₹ mn) | 17,559 | 41,075 | 43,814 | 55,034 | 55,034 | — | — | | DPS (₹) | 4.0 | 5.0 | 6.0 | 10.0 | — | ~11 | ~12 | *Note: FY23–FY26 per S&P Global / StockAnalysis consolidated data; FY27E/28E are our illustrative estimates. Post 2:1 split; EPS restated. P/E on current price. Net income includes investment gains — the "clean" core P/E is higher.* ### Quarterly trajectory (₹ Cr, consolidated) | Quarter | Revenue | Op. profit | OPM | |---|---|---|---| | Jun-24 | 602 | 282 | 47% | | Sep-24 | 813 | 456 | 56% | | **Dec-24 (SEBI F&O curbs)** | **768** | **236** | **31%** | | Mar-25 | 847 | 484 | 57% | | Jun-25 | 958 | 625 | 65% | | Sep-25 | 1,068 | 680 | 64% | | Dec-25 | 1,244 | 732 | 59% | | Mar-26 | 1,564 | 1,041 | 67% | | **Jun-26** | **1,566** | **1,046** | **67%** — *flat QoQ* | ### Revenue mix (FY26) | Segment | ₹ mn | % of revenue | Comment | |---|---|---|---| | Transaction charges | 37,950 | 74% | Options-flow driven; cyclical; regulatory-sensitive | | Services to corporates (listings etc.) | 5,190 | 10% | IPO-cycle linked | | Treasury / clearing-settlement income | 1,714 | 3% | Rate-linked | | Other operating income | 3,485 | 7% | Data / connectivity / vending | | Investment income on own corpus | — | ~6% | On ₹55 bn+ net cash | --- ## Catalysts **Downside (toward our PT):** - Further SEBI derivative-tightening measures (expiry-day rationalization, margin hikes, new levies) - QoQ revenue decline in FY27 prints confirming deceleration; margin normalization below ~60% - NSE product/pricing retaliation compressing BSE's take rate - Indian market drawdown / FII de-risking hitting retail derivatives participation - Regulatory scrutiny of exchange-clearing conflicts or a tech-resilience event **Upside (risks to our view):** - Volume momentum persists; BSE retains/extends its expiry-day advantage - SEBI softens stance; retail F&O participation re-accelerates - New revenue engines scale (India International Exchange flows, data services, clearing corp) - Continued index-inclusion / passive flows into the stock itself --- ## Company Description BSE Ltd (Asia's oldest exchange, est. 1875; listed 2017) operates India's second-largest stock exchange, providing trading in equities, equity derivatives (Sensex/Sensex-50 complex), currencies, debt, and mutual-fund distribution (StAR MF). Revenue is dominated by derivatives transaction charges; the model is asset-light and debt-free, and carries among the highest operating margins (~78% TTM) in Indian financials. ## Analyst Certification & Disclaimer This report was produced by Cline (AI) in the format of a J.P. Morgan-style research note for educational/illustrative purposes. It is **not** J.P. Morgan research; all views, estimates, and the price target herein are AI-generated from public data (Screener.in, StockAnalysis.com / S&P Global, Economic Times, Business Today) as of 27-Aug-2026 and may be inaccurate or outdated. This is not investment advice; consult a SEBI-registered investment adviser before acting.